Bain, Mitsubishi Tanabe Pharma and Japan

Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion
U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
Bain Is Said to Near $3 Billion Deal for Mitsubishi Pharma Unit
Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter said, adding to a dealmaking boom in Japan.
Bain buys 340-year-old pharma company to fast-track Japan’s drug development
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine
Mitsubishi Chemical to sell drug unit to Bain in $3.36 billion deal
Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it seeks to streamline its portfolio.
Bain Capital to Buy Mitsubishi Chemical’s Pharma Business
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key businesses.
Bain Capital Nears Acquisition of Mitsubishi’s Pharma Division in $3.2 Billion Deal
Dubai Bain Capital is in the final stages of negotiations to acquire Mitsubishi Chemical Group’s pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with Mitsubishi Chemical’s strategy to streamline its operations and concentrate on core sectors such as vehicle electrification,
Plastics News16h
Hillenbrand sells majority stake in Milacron machinery business to Bain Capital for $287M
Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron injection molding and extrusion machinery ...
Becker's ASC14h
Why Bain Capital's $3.2B bid for Surgery Partners could 'glaringly outline' PE's impact
Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.
Pensions&Investments18h
Bain Capital chooses capital markets head for real estate division
Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It ...
PE Hub19h
Graham Partners runs CV for Gatekeeper; PACT Capital talks mid-market GP stakes; Bain to acquire Milacron for $287m
Taking a look at a Graham Partners-backed technology company that is pursuing a continuation vehicle funding after running a ...
Bain Capital Announces Majority Investment in Milacron, a Leading Global Provider of Highly Engineered Plastic Processing Solutions
Bain Capital, a leading private investment firm, today announced a majority investment in the Milacron Injection Molding and Extrusion business (or the "Company"), a globally renowned provider of ...
Canadian Plastics1d
Bain Capital buys majority stake in Milacron
An affiliate of Bain Capital will acquire 51 per cent of the injection molding and extrusion machinery maker from current owner Hillenbrand Inc.
PE Hub22h
Bain Capital will acquire manufacturer Milacron
According to the terms of the deal, Bain has agreed to acquire a 51 percent stake in Milacron for $287 million.
Hillenbrand to sell 51% stake in Milacron business to Bain affiliate for $287M
On February 5, the company entered into a definitive agreement to sell an ownership stake of approximately 51% in its Milacron injection ...
Plastics News1d
Hillenbrand sells majority stake in Milacron to Bain Capital for $287M
Hillenbrand Inc. has announced the sale of a 51% stake in its Milacron injection molding and extrusion business to an ...
Bain Capital Specialty Finance issues $350M in senior notes
Bain Capital Specialty Finance , Inc. (NYSE:BCSF), a specialty finance company with a market capitalization of $1.17 billion and trading near its 52-week high of $18.35, announced the issuance of $350 ...